Mabion S.A. is a biotechnology company, researches and develops biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases in Poland. It develops MabionCD20, an oncology drug for the treatment of lymphomas and leukemia blood cancers, as well as rheumatoid arthritis. MabionHER2, an oncology drug for the treatment of breast cancer and MabionVEGF_Fab is a drug for the treatment of various diseases resulting in vision impairment in adults. The company also develops MabionEGFR, an oncology drug for the treatment of metastatic colorectal cancer and MabionVEGF, an oncology drug for the treatment of colon or rectal cancer, metastatic breast cancer, and metastatic or recurrent lung cancer with other anticancer drugs.
Headquarters
ul. Langiewicza 60
Konstantynow Lodzki; Lodzkie;
Postal Code: 95-050
Contact Details: Purchase the Mabion S.A. report to view the information.
Website: http://www.mabion.eu
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service